Mitochondrial & Metabolic

SS-31 (Elamipretide)

For Research Use Only. Not for Human or Veterinary Use.

Overview

SS-31 — also known as Elamipretide (MTP-131) — is a mitochondria-targeted tetrapeptide that selectively binds cardiolipin, a phospholipid of the inner mitochondrial membrane that is essential for cristae structure and for the assembly of the electron-transport chain. By stabilising this membrane it is studied for improving mitochondrial bioenergetics and reducing reactive-oxygen-species production in models of aging, ischemia–reperfusion injury and mitochondrial disease.

Chemical Profile

PropertyValue
CAS number736992-21-5
Other namesElamipretide, MTP-131, Bendavia
ClassMitochondria-targeted tetrapeptide
Amino-acid sequenceH-D-Arg-Dmt-Lys-Phe-NH₂ (Dmt = 2′,6′-dimethyl-L-tyrosine)
Molecular formulaC₃₄H₅₈N₁₀O₆
Molecular weight639.81 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
SS-31 at a glance
Class
Mitochondria-targeted tetrapeptide
Originator
Stealth BioTherapeutics
Research status
Clinical-stage (mitochondrial disease, heart failure)
Study routes
Subcutaneous, intravenous
Half-life
≈ 2–4 h (SC)
Key feature
First-in-class cardiolipin-targeting peptide

Mechanism of Action

SS-31 is a cell-permeable peptide that concentrates at the inner mitochondrial membrane by binding cardiolipin. Cardiolipin holds the cristae folds and the respiratory supercomplexes together, so stabilising it is studied for restoring efficient electron transport, lowering superoxide leakage and improving ATP production.

ComponentDetail
Primary targetCardiolipin in the inner mitochondrial membrane
Binding modeElectrostatic + hydrophobic interaction with cardiolipin
Electron transportStudied for stabilising complex I / III–IV supercomplexes
Permeability transitionInvestigated for preventing mPTP opening
ROSAssociated with reduced superoxide production
Cristae structureStudied for maintaining cristae morphology
SystemStudied effect
Skeletal muscleImproved mitochondrial respiration, reduced fatigue
Cardiac muscleReduced ischemia–reperfusion injury
KidneyMitochondrial preservation in injury models
Brain / retinaBioenergetic support and oxidative-stress reduction

Pharmacology

ParameterValue
Half-life (t½)≈ 2–4 h (SC); ~30–60 min (IV)
Bioavailability (SC)≈ 60–80% (estimated)
Tmax≈ 30–60 min (SC)
Protein binding≈ 90% (albumin)
MetabolismMinimal hepatic; proteolytic degradation
Route of administrationSubcutaneous, intravenous (research)
EliminationRenal (unchanged and fragments)

Research Evidence

SS-31 has an extensive preclinical literature and has been taken into clinical trials for mitochondrial disorders. Representative studies and trial programs are named below; specific numerical outcomes are not restated here as claims.

Preclinical modelResearch focusReference
Aged mouse muscleMitochondrial respiration and oxidative stressSiegel MP, et al.
Cardiac ischemia–reperfusionInfarct size and mitochondrial functionSzeto HH / Dai DF, et al.
Kidney-injury modelsMitochondrial protectionBirk AV, et al.
Clinical programPhaseResearch focusReference
MMPOWER-2 / 3Phase 2–3Primary mitochondrial myopathyStealth BioTherapeutics
EMBRACEPhase 2Heart failureStealth BioTherapeutics
RePOWER / TAZPOWERPhase 2Barth syndromeStealth BioTherapeutics

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Improved mitochondrial respiration; reduced oxidative stressaged muscleSiegel MP et al.
Reduced ischemia–reperfusion injurycardiac / kidney modelsSzeto HH; Birk AV et al.
Clinical-stage in primary mitochondrial myopathyMMPOWER trialsStealth BioTherapeutics

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Reconstitution Reference

Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dose range (literature)≈ 0.5–2 mg daily (SC), in study protocols
Reconstitution solventBacteriostatic water (0.9% benzyl alcohol)
Final concentration≈ 2.5–5 mg/mL
Storage (lyophilized)−20°C, protected from light
Storage (reconstituted)2–8°C, up to ~7 days
Do not useIf the solution is cloudy or contains particulates

Safety Profile

Published research observations, provided for reference only. This material is not for human or veterinary use.

CategoryPublished observations
Local tolerabilityInjection-site reactions reported
GIMild nausea in some studies
CytotoxicityNo cytotoxicity observed
CardiovascularGenerally well tolerated in reported studies
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white lyophilized powder
Solubility (water)Freely soluble (> 100 mg/mL)
logP (octanol/water)≈ −3.5 (hydrophilic)
CharacterBasic tetrapeptide (D-Arg, Lys)
pH (reconstituted)5.0–6.0
Stability (lyophilized)≥ 24 months at −20°C

Synthesis & Manufacturing

SS-31 is a short C-terminally amidated tetrapeptide made by Fmoc solid-phase synthesis. The non-standard residues — D-arginine and 2′,6′-dimethyltyrosine (Dmt) — are the parts that require dedicated building blocks.

StepDetail
StrategyFmoc solid-phase peptide synthesis
ResinRink amide MBHA resin (C-terminal amide)
Special residuesD-Arg and Dmt (dimethyltyrosine) building blocks
CouplingHBTU / HOBt with DIPEA
CleavageTFA / TIPS / H₂O (95 : 2.5 : 2.5)
PurificationPreparative RP-HPLC (C18, TFA/ACN gradient)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. Confirm the non-standard residues (D-arginine and 2′,6′-dimethyltyrosine) by chiral / amino-acid analysis.

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, low-organic TFA/ACN gradientSingle main peak
ESI-MS (positive mode)Identity / mass[M+H]⁺ ≈ 640 Da
MALDI-TOFMass confirmation[M+H]⁺ ≈ 640 Da
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: low-organic TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 640 Da). Confirm the non-standard residues (D-arginine and 2′,6′-dimethyltyrosine) by chiral / amino-acid analysis.

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark≥ 12 monthsMinimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)3 months< 5% degradation
Reconstituted, 2–8°C, dark7–14 daysMinor degradation
Reconstituted, 25°C24–48 hUse promptly
Light exposure (ICH Q1B)1.2 M lux·hGenerally light-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable — aliquot to avoid repeats
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: Confirm the non-standard residues (D-arginine and 2′,6′-dimethyltyrosine) by chiral / amino-acid analysis.

Selected References

  • Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology.
  • Siegel MP, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell.
  • Birk AV, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS; special residues (D-Arg, Dmt) verified
  • Research samples through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need SS-31 — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote